Divozilimab

• CAT Number: I042080
• CAS Number: 2254061-60-2
• Purity: ≥95%

Divozilimab（Cat No.:I042080）is an investigational monoclonal antibody that targets the PD-1 receptor (programmed cell death protein 1), a key immune checkpoint involved in suppressing T-cell activity. By blocking PD-1, divozilimab aims to enhance immune system activity, allowing T-cells to better recognize and attack cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including non-small cell lung cancer (NSCLC) and melanoma. The goal is to assess its safety, efficacy, and its potential to improve cancer treatment outcomes, either alone or in combination with other therapies.